Applications of N5-[[[(2,3-Dihydro-2,2,4,6,7-Pentamethyl-5-Benzofuranyl)Sulfonyl]Amino]Iminomethyl]-D-Ornithine in Industrial Manufacturing

Our facility supplies N5-[[[(2,3-Dihydro-2,2,4,6,7-Pentamethyl-5-Benzofuranyl)Sulfonyl]Amino]Iminomethyl]-D-Ornithine for advanced industrial applications in strict compliance with global quality and safety standards. The following sections detail real downstream uses across specialty chemical, pharmaceutical, and biochemical sectors, with emphasis on actual regulatory requirements and technical production details.

1. Peptide API Intermediate Synthesis

This material serves as an essential protected amino acid derivative for peptide synthesis, especially for custom APIs targeting rare disease treatments and complex peptide drugs. Manufacturers use it at the side-chain modification step to introduce steric bulk and enhance metabolic stability without triggering side reactions. The compound’s sterically hindered sulfonyl group provides unique benefits for orthogonal deprotection in multi-step solid-phase synthesis workflows. Quality control includes in-depth LC-MS and NMR characterization at every coupling and cleavage cycle, supporting cGMP-grade production throughout the entire value chain.

Industry compliance standards

• ICH Q7: Good Manufacturing Practice for Active Pharmaceutical Ingredients
• USP General Chapter <1078> Good Storage and Shipping Practices
• EU GMP Part II (API)
• FDA 21 CFR Part 210/211 (Drug Product CGMP)

Typical usage ratio

• 0.8–1.1 molar equivalents per coupling step, adjusted for peptide sequence hydrophobicity and steric effects.

Downstream process integration

• Incorporated at the protected amino acid loading stage on the resin.
• Processed through standard Fmoc/tBu or Boc chemistry deprotection cycles.
• Final deprotection and global cleavage performed after chain assembly.

Final product types

• Peptide-based APIs for injectable, nasal, and oral peptide drugs
• Modified peptide building blocks
• Peptide conjugate intermediates
• Specialty research-grade peptides

2. Enzyme Inhibitor Precursor in Drug Discovery

Medicinal chemistry teams rely on this compound as a privileged scaffold for novel irreversible enzyme inhibitor candidates, especially those targeting serine proteases and other peptidase classes. Its structure enables exploration of both P1 and P1’ activities while providing reliable selectivity. The compound’s stability profile supports direct use in high-throughput synthesis and screening workflows. Our process enables full regulatory traceability and comprehensive material safety data as required for IND-supporting batches.

Industry compliance standards

• OECD Series on Good Laboratory Practice (GLP)
• ISO 9001:2015 Quality Management Systems Certification
• REACH Registration (EC 1907/2006, if for EU R&D)
• IUPAC chemical identity confirmation

Typical usage ratio

• 0.1–10 mmol scale per synthesis batch, scaled to HTS plate or lead optimization phase.

Downstream process integration

• Used in parallel synthesis platforms for combinatorial chemistry.
• Reacted under standard amide coupling or substituted derivative pathways.
• Purifications via silica chromatography or preparative HPLC as protocol allows.

Final product types

• Enzyme inhibitor drug leads
• Diagnostic reagents for protease activity
• Structure-activity relationship (SAR) libraries
• Mechanistic biochemical probes

3. Advanced Biomedical Polymers and Hydrogels

Biomedical material manufacturers introduce this ornithine derivative as a functional monomer or cross-linker to improve the bioactivity and mechanical strength of medical-grade hydrogels and smart polymer systems. The bulky benzofuranyl sulfonyl group grants improved resistance to enzymatic degradation under physiological conditions, benefiting implantable and injectable devices. Manufacturers tune polymerization and cross-link density by controlling monomer ratios, pH, and temperature during synthesis. All batches undergo endotoxin clearance and bioburden control per device specifications.

Industry compliance standards

• ISO 13485:2016 (Medical Devices Quality Management)
• USP Class VI Biological Reactivity Tests
• ISO 11137 (Sterilization of Health Care Products)
• FDA 21 CFR 820 (Quality System Regulation for Medical Devices)

Typical usage ratio

• 1–5% w/w as a functional comonomer, adjusted per hydrogel formulation to balance elasticity and degradation rate.

Downstream process integration

• Dissolved or dispersed in monomer mix prior to polymerization.
• Cross-linking via UV, thermal, or chemical initiation, depending on processing equipment.
• Post-synthesis purification through dialysis and sterilization.

Final product types

• Implantable wound dressings with controlled drug release
• Injectable tissue scaffolds for regenerative medicine
• Bioactive coatings for medical devices
• Cell encapsulation hydrogels

4. Specialty Analytical Reagents for Proteomics

This compound is adopted as an innovative derivatization reagent for quantitative proteomics and peptide mapping workflows. Analytical reagent suppliers use it to improve peptide ionization efficiency and retention in LC-MS platforms. The unique benzofuranyl moiety enables accurate site-specific labeling and supports quantification at low detection limits. All production follows controlled batch records, validated purification, and meets LC-MS reagent quality requirements, with CoA and trace contaminant documentation provided for each shipment.

Industry compliance standards

• ISO/IEC 17025 (Testing and Calibration Laboratories)
• EN ISO 8655 (Pipette Preparation and Calibration, for analytical workflow)
• GLP for Analytical Laboratories (OECD)
• Supplier specification for low endotoxin and heavy metal contamination

Typical usage ratio

• 0.2–2.0 molar equivalents relative to peptide analyte, titrated by sample complexity and required labeling stoichiometry.

Downstream process integration

• Dissolved into acetonitrile or aqueous buffer just prior to sample derivatization.
• Incubated with peptide/protein digests under controlled pH and temperature for labeling reaction.
• Excess reagent quenched or removed by filtration before MS analysis.

Final product types

• Quantitative peptide standards
• MS-labeling kits for proteomics vendors
• LC-MS test mixes for calibration
• Labeled reference materials for pharmaceutical QC labs